Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-α and IL-4 stimulated human lung fibroblast

Akiko Rokudai, Yasuhito Terui, Ryoko Kuniyoshi, Yuji Mishima, Yuko Mishima, Eriko Yokota, Yoshiko Sonoda, Tadashi Kasahara, Kiyohiko Hatake

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Allergic asthma and allergic dermatitis are chronic inflammatory diseases and are characterized by an accumulation of eosinophils at sites of inflammation. Eotaxin-1/CCL11 and eotaxin-3/CCL26 are members of the CC chemokine family, which are known to be potent chemoattractants for eosinophils. We observed that a human lung fibroblast, HFL-1 produces eotaxin-1 and -3 in response to TNF-α plus IL-4 stimulation, accompanied with NF-κB and STAT6 activation. We explored which signaling pathways are operative in the production of eotaxin-1 and -3 using several inhibitors. Eotaxin-1/CCL11 production was inhibited by a p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580, but not by the MEK (MAPK/ERK kinase) inhibitors, PD98059 and U0126. In contrast, eotaxin-3/CCL26 production was inhibited similarly by PD98059 as well as U0126 and SB203580. In addition, two proteasome inhibitors, N-acetyl-leucyl-leucyl-norleucinal (ALLN) and bortezomib with significant inhibitory activity on NF-κB activation, inhibited eotaxin-1/CCL11 production with IC50 8 μM for ALLN and IC50 16 nM for bortezomib. In contrast, eotaxin-3/CCL26 production was not inhibited significantly up to 10 μM of ALLN (IC50 16 μM) and up to 10 nM of bortezomib (IC50 11 nM), giving inhibition of eotaxin-3/CCL26 less sensitive than eotaxin-1/CCL11 production by the proteasome inhibitors. Synergistic inhibition was observed among lower doses of SB203580 and proteasome inhibitors, particularly in the eotaxin-1/CCL11 production. No such prominent synergism was found on the eotaxin-3/CCL26 production. The suppression of eotaxin family production by these inhibitors may be efficacious against allergic diseases.

Original languageEnglish
Pages (from-to)1102-1109
Number of pages8
JournalBiological and Pharmaceutical Bulletin
Volume29
Issue number6
DOIs
Publication statusPublished - 2006 Jun

Fingerprint

Chemokine CCL11
Interleukin-4
Fibroblasts
Lung
Inhibitory Concentration 50
Proteasome Inhibitors
Eosinophils
CC Chemokines
Chemotactic Factors
Mitogen-Activated Protein Kinase Kinases
p38 Mitogen-Activated Protein Kinases
Dermatitis
Protein Kinase Inhibitors
Chronic Disease
Asthma
Inflammation

Keywords

  • Eotaxin-1
  • Eotaxin-3
  • Lung fibroblast
  • NF-κB activation
  • Proteasome inhibitor

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-α and IL-4 stimulated human lung fibroblast. / Rokudai, Akiko; Terui, Yasuhito; Kuniyoshi, Ryoko; Mishima, Yuji; Mishima, Yuko; Yokota, Eriko; Sonoda, Yoshiko; Kasahara, Tadashi; Hatake, Kiyohiko.

In: Biological and Pharmaceutical Bulletin, Vol. 29, No. 6, 06.2006, p. 1102-1109.

Research output: Contribution to journalArticle

Rokudai, Akiko ; Terui, Yasuhito ; Kuniyoshi, Ryoko ; Mishima, Yuji ; Mishima, Yuko ; Yokota, Eriko ; Sonoda, Yoshiko ; Kasahara, Tadashi ; Hatake, Kiyohiko. / Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-α and IL-4 stimulated human lung fibroblast. In: Biological and Pharmaceutical Bulletin. 2006 ; Vol. 29, No. 6. pp. 1102-1109.
@article{1402739e09374955b5541105ae8fd760,
title = "Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-α and IL-4 stimulated human lung fibroblast",
abstract = "Allergic asthma and allergic dermatitis are chronic inflammatory diseases and are characterized by an accumulation of eosinophils at sites of inflammation. Eotaxin-1/CCL11 and eotaxin-3/CCL26 are members of the CC chemokine family, which are known to be potent chemoattractants for eosinophils. We observed that a human lung fibroblast, HFL-1 produces eotaxin-1 and -3 in response to TNF-α plus IL-4 stimulation, accompanied with NF-κB and STAT6 activation. We explored which signaling pathways are operative in the production of eotaxin-1 and -3 using several inhibitors. Eotaxin-1/CCL11 production was inhibited by a p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580, but not by the MEK (MAPK/ERK kinase) inhibitors, PD98059 and U0126. In contrast, eotaxin-3/CCL26 production was inhibited similarly by PD98059 as well as U0126 and SB203580. In addition, two proteasome inhibitors, N-acetyl-leucyl-leucyl-norleucinal (ALLN) and bortezomib with significant inhibitory activity on NF-κB activation, inhibited eotaxin-1/CCL11 production with IC50 8 μM for ALLN and IC50 16 nM for bortezomib. In contrast, eotaxin-3/CCL26 production was not inhibited significantly up to 10 μM of ALLN (IC50 16 μM) and up to 10 nM of bortezomib (IC50 11 nM), giving inhibition of eotaxin-3/CCL26 less sensitive than eotaxin-1/CCL11 production by the proteasome inhibitors. Synergistic inhibition was observed among lower doses of SB203580 and proteasome inhibitors, particularly in the eotaxin-1/CCL11 production. No such prominent synergism was found on the eotaxin-3/CCL26 production. The suppression of eotaxin family production by these inhibitors may be efficacious against allergic diseases.",
keywords = "Eotaxin-1, Eotaxin-3, Lung fibroblast, NF-κB activation, Proteasome inhibitor",
author = "Akiko Rokudai and Yasuhito Terui and Ryoko Kuniyoshi and Yuji Mishima and Yuko Mishima and Eriko Yokota and Yoshiko Sonoda and Tadashi Kasahara and Kiyohiko Hatake",
year = "2006",
month = "6",
doi = "10.1248/bpb.29.1102",
language = "English",
volume = "29",
pages = "1102--1109",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "6",

}

TY - JOUR

T1 - Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-α and IL-4 stimulated human lung fibroblast

AU - Rokudai, Akiko

AU - Terui, Yasuhito

AU - Kuniyoshi, Ryoko

AU - Mishima, Yuji

AU - Mishima, Yuko

AU - Yokota, Eriko

AU - Sonoda, Yoshiko

AU - Kasahara, Tadashi

AU - Hatake, Kiyohiko

PY - 2006/6

Y1 - 2006/6

N2 - Allergic asthma and allergic dermatitis are chronic inflammatory diseases and are characterized by an accumulation of eosinophils at sites of inflammation. Eotaxin-1/CCL11 and eotaxin-3/CCL26 are members of the CC chemokine family, which are known to be potent chemoattractants for eosinophils. We observed that a human lung fibroblast, HFL-1 produces eotaxin-1 and -3 in response to TNF-α plus IL-4 stimulation, accompanied with NF-κB and STAT6 activation. We explored which signaling pathways are operative in the production of eotaxin-1 and -3 using several inhibitors. Eotaxin-1/CCL11 production was inhibited by a p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580, but not by the MEK (MAPK/ERK kinase) inhibitors, PD98059 and U0126. In contrast, eotaxin-3/CCL26 production was inhibited similarly by PD98059 as well as U0126 and SB203580. In addition, two proteasome inhibitors, N-acetyl-leucyl-leucyl-norleucinal (ALLN) and bortezomib with significant inhibitory activity on NF-κB activation, inhibited eotaxin-1/CCL11 production with IC50 8 μM for ALLN and IC50 16 nM for bortezomib. In contrast, eotaxin-3/CCL26 production was not inhibited significantly up to 10 μM of ALLN (IC50 16 μM) and up to 10 nM of bortezomib (IC50 11 nM), giving inhibition of eotaxin-3/CCL26 less sensitive than eotaxin-1/CCL11 production by the proteasome inhibitors. Synergistic inhibition was observed among lower doses of SB203580 and proteasome inhibitors, particularly in the eotaxin-1/CCL11 production. No such prominent synergism was found on the eotaxin-3/CCL26 production. The suppression of eotaxin family production by these inhibitors may be efficacious against allergic diseases.

AB - Allergic asthma and allergic dermatitis are chronic inflammatory diseases and are characterized by an accumulation of eosinophils at sites of inflammation. Eotaxin-1/CCL11 and eotaxin-3/CCL26 are members of the CC chemokine family, which are known to be potent chemoattractants for eosinophils. We observed that a human lung fibroblast, HFL-1 produces eotaxin-1 and -3 in response to TNF-α plus IL-4 stimulation, accompanied with NF-κB and STAT6 activation. We explored which signaling pathways are operative in the production of eotaxin-1 and -3 using several inhibitors. Eotaxin-1/CCL11 production was inhibited by a p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580, but not by the MEK (MAPK/ERK kinase) inhibitors, PD98059 and U0126. In contrast, eotaxin-3/CCL26 production was inhibited similarly by PD98059 as well as U0126 and SB203580. In addition, two proteasome inhibitors, N-acetyl-leucyl-leucyl-norleucinal (ALLN) and bortezomib with significant inhibitory activity on NF-κB activation, inhibited eotaxin-1/CCL11 production with IC50 8 μM for ALLN and IC50 16 nM for bortezomib. In contrast, eotaxin-3/CCL26 production was not inhibited significantly up to 10 μM of ALLN (IC50 16 μM) and up to 10 nM of bortezomib (IC50 11 nM), giving inhibition of eotaxin-3/CCL26 less sensitive than eotaxin-1/CCL11 production by the proteasome inhibitors. Synergistic inhibition was observed among lower doses of SB203580 and proteasome inhibitors, particularly in the eotaxin-1/CCL11 production. No such prominent synergism was found on the eotaxin-3/CCL26 production. The suppression of eotaxin family production by these inhibitors may be efficacious against allergic diseases.

KW - Eotaxin-1

KW - Eotaxin-3

KW - Lung fibroblast

KW - NF-κB activation

KW - Proteasome inhibitor

UR - http://www.scopus.com/inward/record.url?scp=33744946280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744946280&partnerID=8YFLogxK

U2 - 10.1248/bpb.29.1102

DO - 10.1248/bpb.29.1102

M3 - Article

VL - 29

SP - 1102

EP - 1109

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 6

ER -